The following pages link to orphan drug (Q1367466):
Displaying 50 items.
- Shire plc (Q905049) (← links)
- Swedish Orphan Biovitrum (Q7654795) (← links)
- Category:Orphan drugs (Q9052781) (← links)
- The prevalence and cost of unapproved uses of top-selling orphan drugs (Q21134770) (← links)
- Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries (Q26785430) (← links)
- The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review (Q26801751) (← links)
- World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients (Q26826936) (← links)
- Effectiveness, safety and costs of orphan drugs: an evidence-based review (Q26827237) (← links)
- The current status of orphan drug development in Europe and the US (Q26830502) (← links)
- Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives (Q27005639) (← links)
- Brand-name drug, generic drug, orphan drug. Pharmacological therapy with biosimilar drugs - provision of due diligence in the treatment process (Q27006884) (← links)
- Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China (Q28070073) (← links)
- The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development (Q28088277) (← links)
- What makes an orphan drug? (Q28298527) (← links)
- Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs (Q28468294) (← links)
- Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage (Q28468454) (← links)
- Profitability and Market Value of Orphan Drug Companies: A Retrospective, Propensity-Matched Case-Control Study (Q28552860) (← links)
- Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis (Q28553714) (← links)
- Dornase-alfa and orphan drugs (Q30053536) (← links)
- US Food and Drug Administration Approval of Liposomal Amphotericin B for the Treatment of Visceral Leishmaniasis: A Model for Orphan Drug Development (Q30306478) (← links)
- Orphan drugs: expensive yet necessary. (Q30369009) (← links)
- Orphan drugs and the NHS: should we value rarity? (Q30476322) (← links)
- Clinical trial transparency and orphan drug development: recent trends in data sharing by the pharmaceutical industry (Q30486688) (← links)
- Reimbursement of orphan drugs in Belgium: what (else) matters? (Q30587491) (← links)
- The Budget Impact of Orphan Drugs In The Us and Canada: A 2007-2013 Midas Sales Data Analysis (Q31016895) (← links)
- What Can Big Data Offer the Pharmacovigilance of Orphan Drugs? (Q31146728) (← links)
- (Q31890004) (redirect page) (← links)
- Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate (Q33564338) (← links)
- The economics of orphan drug policy in the US. Can the legislation be improved? (Q33571804) (← links)
- The US orphan drug programme 1983-1995. (Q33576656) (← links)
- Determinants of orphan drugs prices in France: a regression analysis (Q33587572) (← links)
- Shining a light in the black box of orphan drug pricing (Q33602241) (← links)
- A comparative study of orphan drug prices in Europe (Q33604660) (← links)
- Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe (Q33604678) (← links)
- New Financial and Research Models for Pediatric Orphan Drug Development - Focus on the NCATS TRND Program (Q33621814) (← links)
- Insurance companies' perspectives on the orphan drug pipeline (Q33714906) (← links)
- Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries (Q33840393) (← links)
- Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice (Q33840472) (← links)
- Orphan drug pricing and payer management in the United States: are we approaching the tipping point? (Q33932212) (← links)
- The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? (Q34090111) (← links)
- Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism (Q34136688) (← links)
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67 (Q34152580) (← links)
- Accelerating orphan drug development (Q34152583) (← links)
- Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer (Q34189974) (← links)
- Pricing and reimbursement of orphan drugs: the need for more transparency (Q34193502) (← links)
- Systematic review of comparative effectiveness data for oncology orphan drugs. (Q34204588) (← links)
- Rare diseases and orphan drugs: Latvian story (Q34234365) (← links)
- Orphan drug development: an economically viable strategy for biopharma R&D. (Q34256983) (← links)
- Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy (Q34257359) (← links)
- Orphan drugs expenditure in the Netherlands in the period 2006-2012. (Q34333608) (← links)